clinical trial · NCT07802132
A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With Schizophrenia
Zai Lab (Shanghai) Co., Ltd.·—·not yet recruiting·n = 250
Schizophrenia DisorderXanomeline and trospium chloride (KarXT)
brief summary
This study is a prospective, observational, single-arm, open-label, multicenter, real-world study conducted in Chinese adult participants with schizophrenia who meet the International Classification of Diseases (ICD)-10 diagnostic criteria. The total study duration is up to 17 weeks, including a screening/baseline data collection period followed by an observational part during which KarXT treatmentpattern, schizophrenia treatment decisions and compliance will be observed in the real-world setting.
started
Sep 20, 2026
primary completion
Aug 31, 2027
completion
Dec 31, 2028
last updated
Sep 3, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol